Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11199415 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HTTMAPK1MAPTKDM4E | |
| SCHEMBL10340370 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HTTMAPK1MAPTKDM4E | |
| SCHEMBL1663978 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HTTMAPK1CYP3A4TSHR | |
| SCHEMBL30686627 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HTTMAPK1CYP3A4MAPT | |
| SCHEMBL518810 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTMAPK1CYP3A4MAPT | |
| SCHEMBL30382526 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTMAPK1CYP3A4TSHR | |
| SCHEMBL30199709 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HTTMAPK1MAPTKDM4E | |
| SCHEMBL4142866 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HTTMAPK1CYP3A4MAPT | |
| SCHEMBL1897174 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTMAPK1CYP3A4TSHR | |
| SCHEMBL29650091 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPK1CYP3A4TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | claimed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20100324266-A1 | Photocleavable Protecting Groups | AFFYMETRIX, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-06-03 | — | — | US | disclosed |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-06-03 | — | — | US | disclosed |
| EP-2171478-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | The Regents Of The University Of California (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100015092-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | NAKAJIMA SUANNE | 2010-01-21 | — | — | US | disclosed |
| WO-2008121407-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121407-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-09 | — | — | WO | disclosed |
| US-4520197-A | Tetrahydrobenzodiazaphosphorindiones and tetrahydropyridodiazaphosphorindiones | ZOECON CORPORATION (US) | 1985-05-28 | — | — | US | disclosed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | disclosed |
| US-4433149-A | Esters of ureido-phenyl (or pyridyl) phosphinic acids | ZOECON CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | NOX5, TRPM5, MT-ND5 | ALDH1A1 706/4885HTT 1534/4885MAPK1 3055/4885 |
| US-20100015092-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | ALDH1A1 1352/4885HTT 4021/4885MAPK1 1848/4885 |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | ALDH1A1 1331/4885HTT 460/4885MAPK1 2051/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | ALDH1A1 1331/4885HTT 460/4885MAPK1 2051/4885 |
| US-20100324266-A1 | Photocleavable Protecting Groups | POLL, PCNA, ERCC4 | ALDH1A1 1340/4885HTT 1552/4885MAPK1 2035/4885 |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | SULT1A1, SULT2A1, TPST2 | ALDH1A1 232/4885HTT 928/4885MAPK1 3201/4885 |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | ALDH1A1 2044/4885HTT 1801/4885MAPK1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.